Shots:
- AstraZeneca has reported P-III (BaxHTN) trial findings on baxdrostat in pts with uncontrolled hypertension on two antihypertensives & those with resistant hypertension on ≥3 drugs, incl. a diuretic
- The P-III (BaxHTN) trial evaluated baxdrostat (1 or 2mg) vs PBO on top of SoCs in 796 pts over 12wks. At Wk. 24, 300 pts on baxdrostat (2mg) were re-randomized to continue treatment or switch to PBO for 8wks., with long-term safety assessed at Wk. 52 vs SoC
- Trial met its 1EP of reduced mean seated systolic blood pressure at 12wks., along with it 2EPs; data to be presented ESC Congress 2025
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News:- AstraZeneca Reports the EC’s Approval for Perioperative Imfinzi to Treat Muscle-Invasive Bladder Cancer (MIBC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
